{"pmid":32416629,"title":"Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines Maarten Vermeer.","text":["Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines Maarten Vermeer.","During severe inflammatory coronavirus infectious disease (CoVID-19) pandemic and based on evidence on COVID-19 epidemiology, patients with primary cutaneous lymphomas (PCLs) have risk for developing complicated COVID-19 infections in consideration of their older age (majority above 60) and their potential underlying predisposing conditions (e.g. hypertension, diabetes).(1,2,3) Moreover, PCL patients with aggressive biologic behavior should be carefully monitored according to guidelines for patients with neoplastic disease.","J Eur Acad Dermatol Venereol","Papadavid, Evangelia","Scaribrick, Julia","Ortiz Romero, Pablo","Guaglino, Pietro","Vermeer, Maarten","Knobler, Robert","Stadler, Rudolf","Bagot, Martine","32416629"],"abstract":["During severe inflammatory coronavirus infectious disease (CoVID-19) pandemic and based on evidence on COVID-19 epidemiology, patients with primary cutaneous lymphomas (PCLs) have risk for developing complicated COVID-19 infections in consideration of their older age (majority above 60) and their potential underlying predisposing conditions (e.g. hypertension, diabetes).(1,2,3) Moreover, PCL patients with aggressive biologic behavior should be carefully monitored according to guidelines for patients with neoplastic disease."],"journal":"J Eur Acad Dermatol Venereol","authors":["Papadavid, Evangelia","Scaribrick, Julia","Ortiz Romero, Pablo","Guaglino, Pietro","Vermeer, Maarten","Knobler, Robert","Stadler, Rudolf","Bagot, Martine"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416629","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/jdv.16593","keywords":["cpvod-19","eortc cltf guidelines","primary cutaneous lymphomas"],"topics":["Prevention"],"weight":1,"_version_":1666991242679943169,"score":9.490897,"similar":[{"pmid":32305989,"title":"Multiple Myeloma in the Time of COVID-19.","text":["Multiple Myeloma in the Time of COVID-19.","We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done in all patients before therapy. For standard-risk patients, we recommend the following: ixazomib, lenalidomide, and dexamethasone (IRd) (preferred), cyclophosphamide lenalidomide and dexamethasone (CRd), daratumumab lenalidomide and dexamethasone (DRd), lenalidomide, bortezomib, and dexamethasone (RVd), or cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For high-risk patients we recommend carfilzomib, lenalidomide, and dexamethasone (KRd) (preferred) or RVd. Decreasing the dose of dexamethasone to 20 mg and giving bortezomib subcutaneously once a week is recommended. We recommend delaying autologous stem cell transplant (ASCT), unless the patient has high-risk disease that is not responding well, or if the patient has plasma cell leukemia (PCL). Testing for COVID-19 should be done before ASCT. If a patient achieves a very good partial response or better, doses and frequency of drug administration can be modified. After 10-12 cycles, lenalidomide maintenance is recommended for standard-risk patients and bortezomib or ixazomib are recommended for high-risk patients. Daratumumab-based regimens are recommended for relapsed patients. Routine ASCT is not recommended for relapse during the epidemic unless the patient has an aggressive relapse or secondary PCL. Patients on current maintenance should continue their therapy.","Acta Haematol","Al Saleh, Abdullah S","Sher, Taimur","Gertz, Morie A","32305989"],"abstract":["We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done in all patients before therapy. For standard-risk patients, we recommend the following: ixazomib, lenalidomide, and dexamethasone (IRd) (preferred), cyclophosphamide lenalidomide and dexamethasone (CRd), daratumumab lenalidomide and dexamethasone (DRd), lenalidomide, bortezomib, and dexamethasone (RVd), or cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For high-risk patients we recommend carfilzomib, lenalidomide, and dexamethasone (KRd) (preferred) or RVd. Decreasing the dose of dexamethasone to 20 mg and giving bortezomib subcutaneously once a week is recommended. We recommend delaying autologous stem cell transplant (ASCT), unless the patient has high-risk disease that is not responding well, or if the patient has plasma cell leukemia (PCL). Testing for COVID-19 should be done before ASCT. If a patient achieves a very good partial response or better, doses and frequency of drug administration can be modified. After 10-12 cycles, lenalidomide maintenance is recommended for standard-risk patients and bortezomib or ixazomib are recommended for high-risk patients. Daratumumab-based regimens are recommended for relapsed patients. Routine ASCT is not recommended for relapse during the epidemic unless the patient has an aggressive relapse or secondary PCL. Patients on current maintenance should continue their therapy."],"journal":"Acta Haematol","authors":["Al Saleh, Abdullah S","Sher, Taimur","Gertz, Morie A"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305989","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1159/000507690","keywords":["covid-19","multiple myeloma","recommendations"],"e_drugs":["Cyclophosphamide","carfilzomib","Bortezomib","ixazomib","daratumumab","Dexamethasone","Lenalidomide"],"topics":["Prevention"],"weight":1,"_version_":1666138493401694208,"score":132.65216},{"pmid":32389999,"title":"Analysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the Fight Against COVID-19 in China.","text":["Analysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the Fight Against COVID-19 in China.","BACKGROUND The aim of this study was to understand the changes in psychological factors and sleep status of front-line medical staff in the fight against COVID-19 and provide evidence of exercise interventions to relieve psychological stress and improve sleep status for medical staff. MATERIAL AND METHODS A survey study was conducted among 120 front-line medical staff in the fight against COVID-19, of which 60 medical staff worked at the designated hospital (experimental group) and 60 medical staff worked at the non-designated hospital (control group). The Symptom Checklist 90 (SCL-90), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and PTSD Checklist-Civilian Version (PCL-C) were used to assess mental status. Sleep status was assessed using the Pittsburgh Sleep Quality Index (PSQI). RESULTS SCL-90 scores of somatization, depression, anxiety, and terror were higher than normal in front-line medical staff at the designated hospital. The SAS (45.89+/-1.117), SDS (50.13+/-1.813), and PCL-C (50.13+/-1.813) scores in the experimental group were higher than the normal control group, and were significantly different from those in the control group on SDS and PCL-C scales (P<0.05). The total average PSQI of the experimental group was 16.07+/-3.761, indicating that the sleep quality was poor. Among them, participants with moderate insomnia reached 61.67%, and participants with severe insomnia reached 26.67%. CONCLUSIONS There are psychological symptoms and sleep symptoms in front-line medical staff who participate in the fight against COVID-19, and they affect each other. Hospitals should improve emergency management measures, strengthen psychological counseling for clinical front-line medical staff, strengthen exercise intervention, and improve their sleep quality and mental health.","Med Sci Monit Basic Res","Wu, Koulong","Wei, Xuemei","32389999"],"abstract":["BACKGROUND The aim of this study was to understand the changes in psychological factors and sleep status of front-line medical staff in the fight against COVID-19 and provide evidence of exercise interventions to relieve psychological stress and improve sleep status for medical staff. MATERIAL AND METHODS A survey study was conducted among 120 front-line medical staff in the fight against COVID-19, of which 60 medical staff worked at the designated hospital (experimental group) and 60 medical staff worked at the non-designated hospital (control group). The Symptom Checklist 90 (SCL-90), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and PTSD Checklist-Civilian Version (PCL-C) were used to assess mental status. Sleep status was assessed using the Pittsburgh Sleep Quality Index (PSQI). RESULTS SCL-90 scores of somatization, depression, anxiety, and terror were higher than normal in front-line medical staff at the designated hospital. The SAS (45.89+/-1.117), SDS (50.13+/-1.813), and PCL-C (50.13+/-1.813) scores in the experimental group were higher than the normal control group, and were significantly different from those in the control group on SDS and PCL-C scales (P<0.05). The total average PSQI of the experimental group was 16.07+/-3.761, indicating that the sleep quality was poor. Among them, participants with moderate insomnia reached 61.67%, and participants with severe insomnia reached 26.67%. CONCLUSIONS There are psychological symptoms and sleep symptoms in front-line medical staff who participate in the fight against COVID-19, and they affect each other. Hospitals should improve emergency management measures, strengthen psychological counseling for clinical front-line medical staff, strengthen exercise intervention, and improve their sleep quality and mental health."],"journal":"Med Sci Monit Basic Res","authors":["Wu, Koulong","Wei, Xuemei"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389999","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.12659/MSMBR.924085","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1666528580238049280,"score":124.1643},{"pmid":32277351,"title":"Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.","text":["Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.","Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed.","Am J Clin Dermatol","Torres, Tiago","Puig, Luis","32277351"],"abstract":["Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed."],"journal":"Am J Clin Dermatol","authors":["Torres, Tiago","Puig, Luis"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277351","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s40257-020-00514-2","topics":["Prevention"],"weight":1,"_version_":1666138491600240641,"score":120.42426},{"pmid":32478867,"title":"Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.","text":["Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.","During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >/=T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >/=T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.","Cancer","Baumann, Brian C","MacArthur, Kelly M","Brewer, Jerry D","Mendenhall, William M","Barker, Christopher A","Etzkorn, Jeremy R","Jellinek, Nathaniel J","Scott, Jeffrey F","Gay, Hiram A","Baumann, John C","Manian, Farrin A","Devlin, Phillip M","Michalski, Jeff M","Lee, Nancy Y","Thorstad, Wade L","Wilson, Lynn D","Perez, Carlos A","Miller, Christopher J","32478867"],"abstract":["During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >/=T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >/=T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic."],"journal":"Cancer","authors":["Baumann, Brian C","MacArthur, Kelly M","Brewer, Jerry D","Mendenhall, William M","Barker, Christopher A","Etzkorn, Jeremy R","Jellinek, Nathaniel J","Scott, Jeffrey F","Gay, Hiram A","Baumann, John C","Manian, Farrin A","Devlin, Phillip M","Michalski, Jeff M","Lee, Nancy Y","Thorstad, Wade L","Wilson, Lynn D","Perez, Carlos A","Miller, Christopher J"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478867","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cncr.32969","keywords":["merkel cell carcinoma","mohs surgery","basal cell carcinoma","coronavirus disease 2019 (covid-19)","cutaneous squamous cell carcinoma","melanoma","radiotherapy","skin cancer","treatment delays"],"locations":["Merkel"],"topics":["Prevention"],"weight":1,"_version_":1668437835182505984,"score":93.6408},{"pmid":32383234,"title":"Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review.","text":["Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review.","COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research. This article is protected by copyright. All rights reserved.","Dermatol Ther","Tang, Keyun","Wang, Yuanzhuo","Zhang, Hanlin","Zheng, Qingyue","Fang, Rouyu","Sun, Qiuning","32383234"],"abstract":["COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Tang, Keyun","Wang, Yuanzhuo","Zhang, Hanlin","Zheng, Qingyue","Fang, Rouyu","Sun, Qiuning"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383234","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dth.13528","keywords":["covid-19","coronavirus","cutaneous manifestations","review","skin"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666267276793348098,"score":93.296135}]}